ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)
Avoiding tolerance against prostatic antigens with subdominant peptide epitopes.
Article in Journal of immunotherapy (Hagerstown, Md. : 1997). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 47 citations in OpenAlex.
- A modified HLA-A*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses.Cellular & molecular immunology · 2018Article
- PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Self-Assembling Peptide Epitopes as Novel Platform for Anticancer Vaccination.Molecular pharmaceutics · 2017Article
- Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform.Oncoimmunology · 2012Article
- CD8+ T-cell cross-competition is governed by peptide-MHC class I stability.European journal of immunology · 2012Article
- Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Cancer biomarker discovery: the entropic hallmark.PloS one · 2010Article
- Optimised electroporation mediated DNA vaccination for treatment of prostate cancer.Genetic vaccines and therapy · 2010Article
- Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival.Vaccine · 2009Article
- Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.Cancer immunology, immunotherapy : CII · 2008Article
- TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
- Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.Cancer immunology, immunotherapy : CII · 2006Article
- Co-administration of a DNA vaccine encoding the prostate specific membrane antigen and CpG oligodeoxynucleotides suppresses tumor growth.Journal of translational medicine · 2004Article
- In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice.Journal of virology · 2004Article
- Hierarchy, tolerance, and dominance in the antitumor T-cell response.Journal of immunotherapy (Hagerstown, Md. : 1997)Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A potential novel therapy for prostate cancer is the induction of immune responses to normal prostate-associated antigens (PAA). One approach is to use synthetic peptides from PAA to educate T cells as a means of developing a defined and specific immunotherapy for prostate cancer. A likely major hurdle when using normal PAA for this type of therapy is the tolerance that the immune system may already have for PAA. To evaluate mechanisms for overcoming tolerance, the authors assessed the level of tolerance to SV40T antigen in a transgenic mouse. The SV40T antigen is selectively expressed in the prostates of mice from the transgenic adenocarcinoma mouse prostate (TRAMP) model. The authors have shown that TRAMP mice are tolerant to a dominant cytotoxic T-lymphocyte (CTL) epitope from the SV40T antigen compared with nontransgenic littermates. The tolerance was exhibited as early as 4 weeks and as late as 24 weeks. The use of multiple injections of an oligonucleotide that contains an unmethylated CpG induced high levels of hematopoiesis but did not overcome the tolerance. Injection of an antibody to activate CD40 increased the CTL response in normal mice but also did not overcome tolerance. However, tolerance in the TRAMP mice was avoided when an epitope that had previously been characterized as a subdominant epitope was administered. The authors are investigating the potential of subdominant epitopes to induce prostatitis and antitumor responses. The results of this work should facilitate the development of immune-based therapies for prostate cancer.
Indexed as
Identifiers
11394501W2329137689What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.